Research programme: HIV-1 fusion inhibitors - Panacos Pharmaceuticals

Drug Profile

Research programme: HIV-1 fusion inhibitors - Panacos Pharmaceuticals

Alternative Names: PA 161

Latest Information Update: 10 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Small molecules
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 05 Mar 2008 A lead compound has been selected for preclinical development
  • 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
  • 19 Apr 2001 Panacos Pharamceuticals enters into a CRADA with the NCI to identify potential candidates for this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top